| Trial ID: | L1336 |
| Source ID: | NCT01847092
|
| Associated Drug: |
Azd1722
|
| Title: |
A Study in CKD Patients With Type 2 Diabetes Mellitus and Albuminuria
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT01847092/results
|
| Conditions: |
Chronic Kidney Disease|Type 2 Diabetes Mellitus
|
| Interventions: |
DRUG: AZD1722|DRUG: Placebo
|
| Outcome Measures: |
Primary: Changes in Urine Albumin to Creatinine Ratio (UACR), The difference between tenapanor and placebo in the change in UACR from baseline to the end of 12 weeks of treatment, Week 12 | Secondary: Change in Estimated Glomerular Filtration Rate (mL/Min/1.73 m2) From Baseline to Week 12 Endpoint, 12 weeks
|
| Sponsor/Collaborators: |
Sponsor: Ardelyx | Collaborators: AstraZeneca
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE2
|
| Enrollment: |
154
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2013-05
|
| Completion Date: |
2015-04
|
| Results First Posted: |
2020-05-27
|
| Last Update Posted: |
2020-05-27
|
| Locations: |
Creekside Endocrine Associates PC, Denver, Colorado, 80209, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT01847092
|
